Table 1

Characteristics of the study populations

Study epoch
CharacteristicEDSS 3–6EDSS 4–6EDSS 6–6.5
Patients (number (% females))1560 (71%)1504 (69%)1231 (67%)
Age at baseline, years (mean±SD)40.9±9.943.0±9.646.5±10.2
Disease duration at baseline, years (median (IQR))9.4 (5.4–14.5)11.1 (6.5–16.7)14.0 (8.9–19.9)
Total recorded follow-up, years (median (IQR))11.1 (7.9–14.5)10.9 (7.7–14.3)11.4 (8.2–15.4)
Annualised relapse rate (mean, median (IQR))
 Prebaseline period0.51, 0.38 (0.01–0.76)0.48, 0.36 (0.08–0.69)0.47, 0.33 (0.00–0.71)
 During epoch0.38, 0.23 (0.00–0.52)0.40, 0.19 (0.00–0.57)0.33, 0.00 (0.00–0.41)
Prebaseline therapy initiations per year (median (IQR))0.12 (0.00–0.33)0.14 (0.00–0.32)0.14 (0.00–0.29)
Patients receiving disease-modifying therapy, number (%)
 Prebaseline period
  Total1017 (65)1074 (71)877 (71)
  Lower efficacy therapy1005 (64)1052 (70)844 (69)
  Higher efficacy therapy82 (5.3)132 (8.8)212 (17)
 During epoch 
  Total1218 (78)1166 (78)770 (63)
  Lower efficacy therapy1132 (73)1044 (69)639 (52)
  Higher efficacy therapy449 (29)440 (29)244 (20)
Proportion of time on therapy (mean, median (IQR))
 Prebaseline period
  Total (%)46, 45 (0–92)51, 59 (0–94)48, 49 (0–89)
  Lower efficacy therapy (%)45, 41 (0–91)48, 51 (0–92)43, 39 (0–83)
  Higher efficacy therapy (%)1, 0 (0–0)2, 0 (0–0)4, 0 (0–0)
 During epoch
  Total (%)64, 90 (20–100)66, 90 (20–100)51, 60 (0–100)
  Lower efficacy therapy (%)51, 54 (0–100)50, 49 (0–100)39, 6 (0–100)
  Higher efficacy therapy (%)13, 0 (0–9)16, 0 (0–14)13, 0 (0–0)
  • EDSS, Expanded Disability Status Scale.